260 related articles for article (PubMed ID: 15607127)
1. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
Ouagued M; Martin-Chouly CA; Brinchault G; Leportier-Comoy C; Depincé A; Bertrand C; Lagente V; Belleguic C; Pruniaux MP
Pulm Pharmacol Ther; 2005; 18(1):49-54. PubMed ID: 15607127
[TBL] [Abstract][Full Text] [Related]
2. Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
Pruniaux MP; Lagente V; Ouaged M; Bertin B; Moreau F; Julien-Larose C; Rocher MN; Leportier C; Martin B; Bouget A; Dubuit JP; Burnouf C; Doherty AM; Bertrand CP
Fundam Clin Pharmacol; 2010 Feb; 24(1):73-82. PubMed ID: 19650853
[TBL] [Abstract][Full Text] [Related]
3. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors.
Martin-Chouly CA; Astier A; Jacob C; Pruniaux MP; Bertrand C; Lagente V
Life Sci; 2004 Jul; 75(7):823-40. PubMed ID: 15183075
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 4 inhibition of beta2-integrin adhesion caused by leukotriene B4 and TNF-alpha in human neutrophils.
Meliton AY; Muñoz NM; Lambertino A; Boetticher E; Learoyd J; Zhu X; Leff AR
Eur Respir J; 2006 Nov; 28(5):920-8. PubMed ID: 16807266
[TBL] [Abstract][Full Text] [Related]
6. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
Rennard SI; Schachter N; Strek M; Rickard K; Amit O
Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413
[TBL] [Abstract][Full Text] [Related]
7. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.
Souza DG; Cassali GD; Poole S; Teixeira MM
Br J Pharmacol; 2001 Nov; 134(5):985-94. PubMed ID: 11682446
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.
Kroegel C; Foerster M
Expert Opin Investig Drugs; 2007 Jan; 16(1):109-24. PubMed ID: 17155857
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
11. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
12. Cilomilast.
Schachter EN
Drugs Today (Barc); 2006 Apr; 42(4):237-47. PubMed ID: 16703120
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Draheim R; Egerland U; Rundfeldt C
J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
[TBL] [Abstract][Full Text] [Related]
14. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
Jones NA; Leport M; Holand T; Vos T; Morgan M; Fink M; Pruniaux MP; Berthelier C; O'Connor BJ; Bertrand C; Page CP
Pulm Pharmacol Ther; 2007; 20(1):60-8. PubMed ID: 16427796
[TBL] [Abstract][Full Text] [Related]
16. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
Compton CH; Gubb J; Nieman R; Edelson J; Amit O; Bakst A; Ayres JG; Creemers JP; Schultze-Werninghaus G; Brambilla C; Barnes NC;
Lancet; 2001 Jul; 358(9278):265-70. PubMed ID: 11498212
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
18. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Giembycz MA
Expert Opin Investig Drugs; 2001 Jul; 10(7):1361-79. PubMed ID: 11772257
[TBL] [Abstract][Full Text] [Related]
19. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
Giembycz MA
Br J Clin Pharmacol; 2006 Aug; 62(2):138-52. PubMed ID: 16842388
[TBL] [Abstract][Full Text] [Related]
20. PDE4 inhibitors in COPD--a more selective approach to treatment.
Vignola AM
Respir Med; 2004 Jun; 98(6):495-503. PubMed ID: 15191033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
